eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

DDD Limited

94 Rickmansworth Road, Watford, Hertfordshire, WD18 7JJ
Telephone: +44 1923 22 9251
Fax: +44 1923 22 0728
WWW: http://www.dddgroup.co.uk
Medical Information Direct Line: +44 1923 22 9251
Medical Information Direct Line: +44 7977989686
Medical Information e-mail: info@dentinox.co.uk
Customer Care direct line: +44 1923 22 9251
Medical Information Fax: +44 1923 220 728

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 14/10/2009
SPC Dentinox Teething Gel


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Dentinox Teething Gel


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Lidocaine Hydrochloride BP 0.33 % w/w

Cetylpyridinium Chloride BP 0.10 % w/w

For full list of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Dental gel

Greenish yellow brown gel.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Dentinox Gel relieves the pain of baby's teething and soothes the gums.


Go to top of the page
4.2 Posology and method of administration

Place a small quantity of Dentinox Teething Gel on a pad of cotton wool or a clean finger and rub gently on baby's gum. Repeat after 20 minutes if necessary. Use when necessary during the teething period.


Go to top of the page
4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients.

Contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.


Go to top of the page
4.4 Special warnings and precautions for use

Keep all medicines out of the sight and reach of children.

Do not use if seal on nozzle is broken.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

Not applicable.


Go to top of the page
4.7 Effects on ability to drive and use machines

Not applicable.


Go to top of the page
4.8 Undesirable effects

None known.


Go to top of the page
4.9 Overdose

We are not aware of any problems caused by overdosage.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Stomatological Preparation, ATC code: A01AD

Cetylpyridium Chloride is a cationic disinfectant which is used for minor wounds, treating superficial infections of the mouth and preserving the product.

Lidocaine Hydrochloride is a local anaesthetic. It works by blocking nerve conduction when applied topically to nerve tissue. It acts on any part of the nervous system and on every type of nerve fibre. For example, when it is applied to the motor cortex, impulse transmission from that area stops, and when it is injected into the skin it prevents the initiation and the transmission of the sensory impulses. A local anaesthetic in contact with a nerve trunk can cause both sensory and motor paralysis in the area innervated. Many kinds of compounds interfere with conduction, but they often permanently damage the nerve cells. The great practical advantage of the local anaesthetics is that their use is reversible, their use is followed by complete recovery in nerve function with no evidence of structural damage to nerve fibres or cells.


Go to top of the page
5.2 Pharmacokinetic properties

Lidocaine produces more prompt, more intense, longer-lasting and more intense anaesthesia than does an equal concentration of procaine. Unlike procaine it is an aminoethylamide. It is an agent of choice, therefore, in individuals sensitive to ester-type local anaesthetics. Lidocaine is relatively quickly absorbed. Lidocaine is metabolised in the liver by mixed-function oxidases by dealkylation to monoethyl glycine and xylidide. The latter compound retains significant local anaesthetic and toxic activity. In man about 75% of xylidide is excreted in the urine as the further metabolite 4-hydroxy-2,6-dimethylaniline. The typical dose of Dentinox gel is about 150mg containing about 0.5mg of lidocaine hydrochloride ( which approximates to about 0.1 mg/kg of bodyweight). Martindale recommends that the total dose of lidocaine hydrochloride should not exceed 200mg (3mg per kg of bodyweight). Thus the dosage of Dentinox Gel is well within this level.


Go to top of the page
5.3 Preclinical safety data

Not applicable.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Purified Water BP

43.34 % w/w

Sorbitol Solution 70 % (non-crystallising) BP

21.00 % w/w

Xylitol HSE

14.00 % w/w

Ethanol 96% BP

9.36 % w/w

Glycerol BP

7.00 % w/w

Hydroxethylcellulose BP

2.50 % w/w

Polyoxyl 40 hydrogenated castor oils

1.00 % w/w

Pharmaceutical Liquid Flavour

0.48 % w/w

Hydroxypolyethoxy Dodecane

0.33 % w/w

Macrogol 300

0.33 % w/w

Sodium Saccharin

0.10 % w/w

Caramel E150

0.07 % w/w

Levomenthol

0.06 % w/w


Go to top of the page
6.2 Incompatibilities

Not applicable


Go to top of the page
6.3 Shelf life

3 years


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C


Go to top of the page
6.5 Nature and contents of container

Internally lacquered aluminium tube, the nozzle of which contains a membrane.

Sachet- 40gsm craft paper, 10 gsm polyethylene, 8 gsm aluminium foil and 30 gsm surlyn.

Pack size 15g (tube), 10g (tube), 1 g sachet

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

DDD Limited,

94, Rickmansworth Road,

Watford,

Hertfordshire,

United Kingdom,

WD1 7JJ.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 00133/5010R


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

19/01/2007


Go to top of the page
10. DATE OF REVISION OF THE TEXT

August 2009



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/22137/SPC/


Active Ingredients/Generics

 
   lidocaine hydrochloride
   cetylpyridinium chloride